SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories reports Profit after tax of Rs 2756.80 Mln, in the September 2020 quarter

07 Nov 2020 Evaluate
The company witnessed a 7.03% growth in the revenue at Rs. 12977.70 millions for the quarter ended September 2020 as compared to Rs. 12125.60 millions during the year-ago period.The company has announced a 40.64% increase in its profits to Rs . 2756.80  millions for the  quarter ended September 2020 compared to Rs. 1960.20 millions in the corresponding quarter in the previous year.Operating Profit saw a handsome growth to 3751.60 millions from 2758.90 millions in the quarter ended September 2020.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202009 201909 % Var 202009 201909 % Var 202003 201903 % Var
Sales 12977.70 12125.60 7.03 27830.20 22235.70 25.16 43674.30 36331.50 20.21
Other Income 150.00 143.30 4.68 266.90 337.60 -20.94 646.90 545.90 18.50
PBIDT 3751.60 2758.90 35.98 9747.90 4903.60 98.79 9794.50 7477.60 30.98
Interest 18.10 40.50 -55.31 42.70 85.20 -49.88 157.90 184.90 -14.60
PBDT 3733.50 2718.40 37.34 9705.20 4818.40 101.42 9636.60 7292.70 32.14
Depreciation 462.60 451.10 2.55 914.90 871.50 4.98 1786.90 1718.80 3.96
PBT 3270.90 2267.30 44.26 8790.30 3946.90 122.71 7849.70 5573.90 40.83
TAX 514.10 307.10 67.40 1497.10 666.20 124.72 1325.10 1024.80 29.30
Deferred Tax -6.90 -18.10 -61.88 -38.90 -24.00 62.08 -54.70 -124.00 -55.89
PAT 2756.80 1960.20 40.64 7293.20 3280.70 122.31 6524.60 4549.10 43.43
Equity 252.70 252.70 0.00 252.70 252.70 0.00 252.70 252.70 0.00
PBIDTM(%) 28.91 22.75 27.05 35.03 22.05 58.83 22.43 20.58 8.96

Ipca Laboratories Share Price

1551.75 -6.15 (-0.39%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×